Gapping down
In reaction to disappointing earnings/guidance:
- CGC -20.8%, DXC -5.9%, CRM -3.3% (also announces multi-year strategic agreement with AT&T), CIR -2.8%, COST -1.8%, TCOM -1.5%, JWN -1.5%, VEEV -1%, OKTA -1%
Other news:
- ARVN -24.2% (announces update on ARV-110)
- AVEO -14.2% (Phase 1b/2 DEDUCTIVE clinical trial update)
- MRNS -13.9% (prices offering of 16 mln shares of common stock at $2.50 per share)
- MMX -9.7% (announces secondary offering and intention to exercise warrants by Pan American Silver)
- NFG -8.1% (prices offering of 3.8 mln shares of common stock at $39.50 per share)
- APPN -4.9% (launches 2.5 mln share offering)
- APY -4.8% (shareholders approve combo with ChampionX)
- ADVM -2.2% (initiates INFINITY Phase 2 trial)
- LAMR -2.2% (cuts dividend in half)
- CGNX -1.5% (announces workforce reduction)
- BOMN -1% (prices offering of 3.2 mln shares of common stock at $16.00 per share)
Analyst comments:
- DEXA -6.3% (downgraded to Neutral from Overweight at JP Morgan)
- HAL -1.8% (downgraded to Market Perform from Outperform at Cowen)
- VFC -1.1% (downgraded to Hold from Buy at Argus)